uniQure (QURE) Misses Q3 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. META
5. FICO
6. LLY
7. TSLA
8. GMAB
9. ACCV
10. CART

Go back to uniQure (QURE) Misses Q3 EPS by 3c

uniQure Announces Financial Results for Third Quarter 2015 and Provides Update on Product Pipeline and Company Developments

November 30, 2015 7:30 AM EST

AMSTERDAM, the Netherlands, Nov. 30, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the third quarter and nine months ending September 30, 2015, and provided an update on its development programs.

"In the last quarter uniQure and our collaborators, a consortium consisting of Institut Pasteur, INSERM, the French Muscular Dystrophy Association and Vaincre les Maladies Lysosomales, have clinically demonstrated proof-of-concept for safely treating a severe lysosomal storage disease, Sanfilippo B, with a gene therapy construct developed by uniQure. The study has shown encouraging... More